Aldevron and Odylia, a nonprofit organization working to develop treatments for ultra-rare ocular diseases using gene therapy, have entered into an agreement in which Aldevron is a member of Odylia.
Under this membership agreement, Aldevron will support Odylia’s mission and activities to advance the research, development, manufacture and commercialization of potential therapeutics that address unmet medical needs for ultra-rare diseases. As part of their partnership, Aldevron will be the exclusive plasmid DNA supplier for Odylia-sponsored programs and products.
“Since its founding 20 years ago, Aldevron has been committed to working with clients and partners to develop products that make a difference in patients’ lives,” commented Michael Chambers, CEO, Aldevron. “Odylia’s unique approach to addressing ultra-rare genetic disorders as a non-profit organization with corporate and other members is an opportunity for us to support this mission. We look forward to working with Odylia and providing them with the high-quality plasmid DNA and other materials that will enable them to bring new products to patients in need.”
“We are pleased to have Aldevron participate directly with Odylia as a member of the organization,” said Scott Dorfman, CEO, Odylia. “Aldevron has an unmatched reputation as a contract manufacturer of plasmid DNA and other materials and our partnership will reduce the time and cost to develop treatments for ultra-rare genetic disorders. We thank Aldevron for their support and continuing commitment to patients.”
Aldevron continues to expand its production scale and product line to support the important work of companies like Odylia. The company’s 70,000 square-foot facility in Fargo, North Dakota, is the largest plasmid DNA production facility in the world and will provide products as critical raw materials for biologics manufacturing as well as drug substances and drug products. Aldevron’s product line includes Cas9 nucleases for gene editing and pALD-X80 for AAV production.
“We are embarking on our next phase of growth and positioning the company to continue to be the premier provider of services and products for the gene editing and gene therapy industries,” added Mr. Chambers.
Aldevron serves the biotechnology industry with custom production of nucleic acids, proteins, and antibodies. Thousands of clients use Aldevron-produced plasmids, RNA and gene editing enzymes for projects ranging from discovery research to clinical trials to commercial applications. These products are critical raw materials and key components in commercially available drugs and medical devices. Aldevron specializes in GMP manufacturing and is known for inventing the GMP-Source™ quality system. Company headquarters are in Fargo, North Dakota, with additional facilities in Madison, Wisconsin, and Freiburg, Germany.
Odylia Therapeutics is a 501(c)(3) nonprofit corporation working to bring treatment for rare eye diseases from the lab into phase I/II/III clinical trials using AAV technology and other gene delivery techniques. There are more than 250 genetic forms of Inherited Retinal Disease (IRD) that lead to blindness. Most are extremely rare, affecting only one in a million people worldwide. Today, there is pre-clinical proof-of-concept for treatments for more than 30 of these diseases, with more being discovered every day. Because these diseases are so rare, there is little commercial interest, leaving Odylia Therapeutics to find a way to move these potential therapies into clinical trials to prevent blindness. For more information, please visit Odylia.org